{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:23:51Z","timestamp":1794072231964,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Department of Science & Technology, Xuzhou, Jiangsu, China","award":["KC20054"],"award-info":[{"award-number":["KC20054"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-94319-0","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T10:36:41Z","timestamp":1742639801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Deletion of ENO1 sensitizes pancreatic cancer cells to gemcitabine via MYC\/RRM1-mediated glycolysis"],"prefix":"10.1038","volume":"15","author":[{"given":"Yingpeng","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"key":"94319_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA-CANCER J. CLIN."},{"key":"94319_CR2","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1053\/j.gastro.2020.10.007","volume":"160","author":"J Huang","year":"2021","unstructured":"Huang, J. et al. Worldwide burden of, risk factors for, and trends in pancreatic cancer. Gastroenterology 160, 744\u2013754 (2021).","journal-title":"GASTROENTEROLOGY"},{"key":"94319_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/14656566.2018.1543402","volume":"20","author":"M Mula","year":"2019","unstructured":"Mula, M. & Sander, J. W. Current and emerging drug therapies for the treatment of depression in adults with epilepsy. Expert Opin. Pharmaco. 20, 41\u201345 (2019).","journal-title":"EXPERT OPIN. PHARMACO"},{"key":"94319_CR4","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HR Burris","year":"1997","unstructured":"Burris, H. R. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403\u20132413 (1997).","journal-title":"J. CLIN. ONCOL."},{"key":"94319_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","volume":"741","author":"CL de Sousa","year":"2014","unstructured":"de Sousa, C. L. & Monteiro, G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur. J. Pharmacol. 741, 8\u201316 (2014).","journal-title":"EUR. J. PHARMACOL."},{"key":"94319_CR6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13046-018-0947-4","volume":"37","author":"M Feng","year":"2018","unstructured":"Feng, M. et al. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. J. Exp. Clin. Cancer Res. 37, 274 (2018).","journal-title":"J. EXP. CLIN. CANC RES."},{"key":"94319_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.drup.2015.10.002","volume":"23","author":"Y Binenbaum","year":"2015","unstructured":"Binenbaum, Y., Na\u2019Ara, S. & Gil, Z. Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resist.  Update 23, 55\u201368 (2015).","journal-title":"DRUG RESIST. UPDATE"},{"key":"94319_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12943-020-01169-7","volume":"19","author":"C Qin","year":"2020","unstructured":"Qin, C. et al. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Mol. Cancer  19, 50 (2020).","journal-title":"MOL. CANCER"},{"key":"94319_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12943-020-01237-y","volume":"19","author":"C Zhou","year":"2020","unstructured":"Zhou, C. et al. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt\/beta-catenin and autophagy pathway through modulating the miR-619-5p\/Pygo2 and miR-619-5p\/ATG14 axes. Mol. Cancer 19, 118 (2020).","journal-title":"MOL. CANCER"},{"key":"94319_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41467-017-00520-9","volume":"8","author":"RC Laker","year":"2017","unstructured":"Laker, R. C. et al. Ampk phosphorylation of Ulk1 is required for targeting of mitochondria to lysosomes in exercise-induced mitophagy. Nat. Commun. 8, 548 (2017).","journal-title":"NAT. COMMUN."},{"key":"94319_CR11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.bbrc.2018.04.137","volume":"500","author":"LY Chen","year":"2018","unstructured":"Chen, L. Y. et al. CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer. Biochem. Biophys. Res. Co 500, 691\u2013697 (2018).","journal-title":"BIOCHEM. BIOPH RES. CO."},{"key":"94319_CR12","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1002\/1873-3468.12744","volume":"591","author":"DG Ryan","year":"2017","unstructured":"Ryan, D. G. & O\u2019Neill, L. Krebs cycle rewired for macrophage and dendritic cell effector functions. Febs Lett. 591, 2992\u20133006 (2017).","journal-title":"FEBS LETT."},{"key":"94319_CR13","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1016\/j.cell.2024.06.026","volume":"187","author":"SM Fendt","year":"2024","unstructured":"Fendt, S. M. 100 Years of the Warburg effect: A cancer metabolism endeavor. Cell 187, 3824\u20133828 (2024).","journal-title":"CELL"},{"key":"94319_CR14","doi-asserted-by":"publisher","first-page":"111713","DOI":"10.1016\/j.yexcr.2019.111713","volume":"386","author":"XX Wang","year":"2020","unstructured":"Wang, X. X. et al. TWIST1 transcriptionally regulates glycolytic genes to promote the Warburg metabolism in pancreatic cancer. Exp. Cell Res. 386, 111713 (2020).","journal-title":"EXP. CELL. RES."},{"key":"94319_CR15","doi-asserted-by":"publisher","first-page":"47691","DOI":"10.18632\/oncotarget.17868","volume":"8","author":"X Qian","year":"2017","unstructured":"Qian, X. et al. Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer. Oncotarget 8, 47691\u201347708 (2017).","journal-title":"Oncotarget"},{"key":"94319_CR16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.7150\/ijms.18736","volume":"14","author":"L Sun","year":"2017","unstructured":"Sun, L. et al. Over-Expression of alpha-enolase as a prognostic biomarker in patients with pancreatic cancer. Int. J. Med. Sci. 14, 655\u2013661 (2017).","journal-title":"INT. J. MED. SCI."},{"key":"94319_CR17","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/mc.23719","volume":"63","author":"H Ma","year":"2024","unstructured":"Ma, H. et al. ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway. Mol. Carcinogen.  63, 1221\u20131234 (2024).","journal-title":"MOL. CARCINOGEN"},{"key":"94319_CR18","doi-asserted-by":"publisher","first-page":"3842198","DOI":"10.1155\/2018\/3842198","volume":"2018","author":"H Yin","year":"2018","unstructured":"Yin, H., Wang, L. & Liu, H. L. ENO1 overexpression in pancreatic cancer patients and its clinical and diagnostic significance. Gastroent. Res. Pract. 2018, 3842198 (2018).","journal-title":"GASTROENT RES. PRACT."},{"key":"94319_CR19","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang, Z. et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45, W98\u2013W102 (2017).","journal-title":"NUCLEIC ACIDS RES."},{"key":"94319_CR20","doi-asserted-by":"crossref","unstructured":"Bartha, A. & Gyorffy, B. TNMplot.com: A web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int. J. Mol. Sci. 22, (2021).","DOI":"10.3390\/ijms22052622"},{"key":"94319_CR21","first-page":"100625","volume":"5","author":"B Gyorffy","year":"2024","unstructured":"Gyorffy, B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation (Camb) 5, 100625 (2024).","journal-title":"Innov. (Camb)"},{"key":"94319_CR22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41420-022-01014-4","volume":"8","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. Lactate promotes the growth of patient-derived organoids from hepatopancreatobiliary cancers via ENO1\/HIF1alpha pathway and does not affect their drug sensitivities. Cell Death Discov.  8, 214 (2022).","journal-title":"CELL. DEATH DISCOV"},{"key":"94319_CR23","first-page":"4470","volume":"11","author":"L Wang","year":"2019","unstructured":"Wang, L., Bi, R., Yin, H., Liu, H. & Li, L. ENO1 silencing impaires hypoxia-induced gemcitabine chemoresistance associated with redox modulation in pancreatic cancer cells. Am. J. Transl. Res. 11, 4470\u20134480 (2019).","journal-title":"AM. J. TRANSL RES."},{"key":"94319_CR24","doi-asserted-by":"publisher","first-page":"8241","DOI":"10.1007\/s11033-022-07540-9","volume":"49","author":"K Zhang","year":"2022","unstructured":"Zhang, K. et al. alpha-enolase inhibits apoptosis and promotes cell invasion and proliferation of skin cutaneous melanoma. Mol. Biol. Rep. 49, 8241\u20138250 (2022).","journal-title":"MOL. BIOL. REP."},{"key":"94319_CR25","doi-asserted-by":"publisher","first-page":"e2220","DOI":"10.1002\/mgg3.2220","volume":"11","author":"H Tang","year":"2023","unstructured":"Tang, H., Pan, L., Tang, L. & Liu, J. Alpha-enolase 1 knockdown facilitates the proliferation and invasion of villous trophoblasts by upregulating COX-2. Mol.  Genet. Genom.  Med. 11, e2220 (2023).","journal-title":"MOL. GENET. GENOM MED."},{"key":"94319_CR26","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.1111\/jcmm.15281","volume":"24","author":"C Hu","year":"2020","unstructured":"Hu, C. et al. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: antitumour activity and molecular mechanism of action. J. Cell Mol. Med. 24, 7239\u20137253 (2020).","journal-title":"J. CELL. MOL. MED."},{"key":"94319_CR27","doi-asserted-by":"publisher","first-page":"917","DOI":"10.18632\/aging.100512","volume":"4","author":"S Mannava","year":"2012","unstructured":"Mannava, S. et al. Ribonucleotide reductase and thymidylate synthase or exogenous deoxyribonucleosides reduce DNA damage and senescence caused by C-MYC depletion. Aging (Albany NY)  4, 917\u2013922 (2012).","journal-title":"Aging (Albany NY)"},{"key":"94319_CR28","unstructured":"Coveler, A. L. et al. A phase 1b\/2 randomized clinical trial of oleclumab with or without durvalumab plus chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma. Clin. Cancer Res. (2024)."},{"key":"94319_CR29","first-page":"285","volume":"5","author":"PA Philip","year":"2020","unstructured":"Philip, P. A. et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol. 5, 285\u2013294 (2020).","journal-title":"LANCET GASTROENTEROL."},{"key":"94319_CR30","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker, M. et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 17, 801\u2013810 (2016).","journal-title":"LANCET ONCOL."},{"key":"94319_CR31","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/MPA.0000000000000314","volume":"44","author":"F Petrelli","year":"2015","unstructured":"Petrelli, F. et al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas 44, 515\u2013521 (2015).","journal-title":"PANCREAS"},{"key":"94319_CR32","doi-asserted-by":"publisher","first-page":"e7287","DOI":"10.1002\/cam4.7287","volume":"13","author":"AC Larson","year":"2024","unstructured":"Larson, A. C., Doty, K. R. & Solheim, J. C. The double life of a chemotherapy drug: Immunomodulatory functions of gemcitabine in cancer. Cancer Med. US  13, e7287 (2024).","journal-title":"CANCER MED-US"},{"key":"94319_CR33","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.20892\/j.issn.2095-3941.2022.0451","volume":"19","author":"H Sun","year":"2022","unstructured":"Sun, H. et al. ENO1 expression and Erk phosphorylation in PDAC and their effects on tumor cell apoptosis in a hypoxic microenvironment. Cancer Biol. Med. 19, 1598\u20131616 (2022).","journal-title":"CANCER BIOL. MED."},{"key":"94319_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-015-0117-5","volume":"8","author":"QF Fu","year":"2015","unstructured":"Fu, Q. F. et al. Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K\/AKT pathway. J. Hematol.  Oncol. 8, 22 (2015).","journal-title":"J. HEMATOL. ONCOL."},{"key":"94319_CR35","doi-asserted-by":"publisher","first-page":"100750","DOI":"10.1016\/j.omto.2023.100750","volume":"31","author":"J Ni","year":"2023","unstructured":"Ni, J., Huang, Y., Li, C., Yin, Q. & Ying, J. Beyond ENO1, emerging roles and targeting strategies of other enolases in cancers. Mol. Ther. Oncolytics  31, 100750 (2023).","journal-title":"MOL. THER-ONCOLYTICS"},{"key":"94319_CR36","doi-asserted-by":"publisher","first-page":"155214","DOI":"10.1016\/j.phymed.2023.155214","volume":"123","author":"X Hu","year":"2024","unstructured":"Hu, X. et al. Shikonin reverses cancer-associated fibroblast-induced gemcitabine resistance in pancreatic cancer cells by suppressing monocarboxylate transporter 4-mediated reverse Warburg effect. Phytomedicine 123, 155214 (2024).","journal-title":"PHYTOMEDICINE"},{"key":"94319_CR37","doi-asserted-by":"crossref","unstructured":"Wang, D., Zhang, P., Liu, Z., Xing\u2019, Y. & Xiao, Y. NXPH4 promotes gemcitabine resistance in bladder cancer by enhancing reactive oxygen species and glycolysis activation through modulating NDUFA4L2. Cancers  14, (2022).","DOI":"10.3390\/cancers14153782"},{"key":"94319_CR38","doi-asserted-by":"crossref","unstructured":"Penny, H. L. et al. Targeting glycolysis in macrophages confers protection against pancreatic ductal adenocarcinoma. Int. J. Mol.  Sci. 22, (2021).","DOI":"10.3390\/ijms22126350"},{"key":"94319_CR39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.canlet.2020.03.015","volume":"479","author":"Y Xi","year":"2020","unstructured":"Xi, Y. et al. hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer. Cancer Lett. 479, 112\u2013122 (2020).","journal-title":"CANCER LETT."},{"key":"94319_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/sj.bjc.6603860","volume":"97","author":"H Ueno","year":"2007","unstructured":"Ueno, H., Kiyosawa, K. & Kaniwa, N. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br. J. Cancer   97, 145\u2013151 (2007).","journal-title":"BRIT J. CANCER"},{"key":"94319_CR41","first-page":"173","volume":"119","author":"H Xie","year":"2013","unstructured":"Xie, H. et al. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer Am.  Cancer Soc. 119, 173\u2013181 (2013).","journal-title":"CANCER-AM CANCER SOC."},{"key":"94319_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/sj.bjc.6603559","volume":"96","author":"Y Nakano","year":"2007","unstructured":"Nakano, Y. et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br. J. Cancer  96, 457\u2013463 (2007).","journal-title":"BRIT J. CANCER"},{"key":"94319_CR43","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1053\/j.gastro.2023.10.026","volume":"166","author":"MC Hasselluhn","year":"2024","unstructured":"Hasselluhn, M. C. et al. An NFATc1\/SMAD3\/cJUN complex restricted to SMAD4-deficient pancreatic cancer guides rational therapies. Gastroenterology 166, 298\u2013312 (2024).","journal-title":"GASTROENTEROLOGY"},{"key":"94319_CR44","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00018-019-03278-z","volume":"77","author":"J Yang","year":"2020","unstructured":"Yang, J. et al. The enhancement of glycolysis regulates pancreatic cancer metastasis. Cell Mol.  Life Sci. 77, 305\u2013321 (2020).","journal-title":"CELL. MOL. LIFE SCI."},{"key":"94319_CR45","first-page":"67","volume":"1870","author":"DE Biancur","year":"2018","unstructured":"Biancur, D. E. & Kimmelman, A. C. The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. BBA Rev. Cancer 1870, 67\u201375 (2018).","journal-title":"BBA-REV CANCER"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94319-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94319-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94319-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T22:48:06Z","timestamp":1742942886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94319-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94319"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94319-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"27 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in compliance with the declaration of Helsinki. Informed consent was obtained from all subjects. The ethics approval statements for human subjects were provided by the Ethnic Committee of the Affiliated Hospital of Xuzhou Medical University (NO. XYFY2015-JS001-01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"9941"}}